William Blank
State University of New York System
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by William Blank.
The Journal of Urology | 2008
Joseph Feliciano; Ervin Teper; Michael N. Ferrandino; Richard J. Macchia; William Blank; Ivan Grunberger; Ivan Colon
PURPOSE Fluoroquinolones have been shown to decrease infective complications after prostate biopsy. However, fluoroquinolone resistance is emerging. We quantified contemporary rates of infective complications and the incidence of fluoroquinolone resistant infections after prostate biopsy under fluoroquinolone prophylaxis. MATERIALS AND METHODS We retrospectively evaluated the records of 1,273 patients who underwent prostate biopsy at New York Harbor Veterans Affairs Hospital from January 2004 to December 2006. Patients received levofloxacin or gatifloxacin. Using the Veterans Affairs computerized patient record system we reviewed all patient visits within 1 month after prostate biopsy. Visits were queried for infective symptoms. Positive cultures were evaluated for resistance patterns. The annual and overall incidence of infective complications and fluoroquinolone resistant infections was calculated. RESULTS Of 1,273 patients 31 (2.4%) presented with infective symptoms after biopsy. The overall incidence of fluoroquinolone resistant infections was 1.2% (15 cases). When stratified by year, there were statistically significant increases in the incidence of infective complications and fluoroquinolone resistance from 2004 to 2006. Of the positive cultures those from 89% of patients yielded Escherichia coli and 90% were fluoroquinolone resistant. Fluoroquinolone resistant E. coli were also resistant to gentamicin in 22% of cases, trimethoprim/sulfamethoxazole in 44%, piperacillin in 72% and ampicillin in 94%. However, 100% sensitivity was demonstrated for amikacin, ceftazidime and ceftriaxone. CONCLUSIONS Fluoroquinolones are still effective as antibiotic prophylaxis for prostate biopsies but there is an increase in infective complications and fluoroquinolone resistance. When patients present with post-prostate biopsy infective symptoms, almost 50% are associated with fluoroquinolone resistant pathogens. Empirical treatment with ceftriaxone, ceftazidime or amikacin should be initiated until culture specific therapy can be implemented.
The Journal of Urology | 1984
William Blank; M.M. Unni Mooppan; B. Chhajwani; Shyan-Yih Chou; Hong Kim
The effects of hypothermia and verapamil, a calcium antagonist, on preventing renal damage after 60 minutes of ischemia were studied in rats. Hypothermia alone provided the best protection, and pretreatment with verapamil failed to afford protective effects in normothermic and hypothermic ischemia, findings further supported by electron microscopic studies.
The Journal of Urology | 1987
Marc Goldstein; William Blank
The Journal of Urology | 2009
Ervin Teper; Ivan Colon; William Blank; Jeffrey P. Weiss; Richard J. Macchia; Nicholas T. Karanikolas
The Journal of Urology | 2009
Alexander Sokol; Ervin Teper; Nicholas T. Karanikolas; Andrew Seymour; Maureen Furnari; William Blank; Richard J. Macchia
The Journal of Urology | 2008
Ervin Teper; Andrew Seymour; Alexander Sokol; Brian Marks; Maureen Furnari; William Blank; Ivan Colon; Richard J. Macchia; Nicholas T. Karanikolas
The Journal of Urology | 2008
Maria Ordonez; Miriam Harel; Ervin Teper; Sophia Chiu; Brent Yanke; William Blank; Ivan Colon; Richard J. Macchia; Nicholas T. Karanikolas
The Journal of Urology | 2007
Joseph Feliciano; Paul Carey; William Blank; Ivan Grunberger; Ivan Colon
The Journal of Urology | 2005
Angelo R. DeRosalia; William Blank
The Journal of Urology | 1987
William Blank; Jian Cao; Marc Goldstein